Core binding factor acute myelogenous leukemia-2021 treatment algorithm
Abstract Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context Riding Helmet Covers of cytarabine based intensive chemotherapy.Still, outcome can be improved significantly through the effective implementation of ava